NewsBenzingaTeradyne prevede un EPS rettificato del Q4 di $1,95-$2,25 contro stima di $2,01; prevede vendite di $1,250M-$1,350M contro stima di $1,261B Teradyne prevede un EPS rettificato del Q4 di $1,95-$2,25 contro stima di $2,01; prevede vendite di $1,250M-$1,350M contro stima di $1,261B Benzinga 2026.10.27 20:33 (GMT+0) Open on Benzinga Other news Wolfe Research Initiates Coverage On Monster Beverage with Outperform Rating Druckenmiller Buys Miners, Warns '27 Could Be 'Disappointing' Wolfe Research Initiates Coverage On Keurig Dr Pepper with Outperform Rating, Announces Price Target of $42 Wolfe Research Initiates Coverage On PepsiCo with Peer Perform Rating BTIG Reiterates Neutral on FuboTVto Neutral Bitcoin Erases Summer Rally as ETF Outflows Persist
Wolfe Research Initiates Coverage On Keurig Dr Pepper with Outperform Rating, Announces Price Target of $42